Aia Group LTD Seagen Inc. Transaction History

Aia Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$187.64 - $206.25 $501,186 - $550,893	-2,671 Reduced 29.27%	6,455 $1.24 Million
Q1 2023 Apr 28, 2023	BUY	$127.59 - $203.08 $51,929 - $82,653	407 Added 4.67%	9,126 $1.85 Million
Q4 2022 Jan 31, 2023	SELL	$117.37 - $139.17 $1.09 Million - $1.3 Million	-9,328 Reduced 51.69%	8,719 $1.12 Million
Q3 2022 Nov 04, 2022	BUY	$135.27 - $180.11 $1.48 Million - $1.96 Million	10,906 Added 152.72%	18,047 $2.47 Million
Q2 2022 Aug 11, 2022	BUY	$108.81 - $179.33 $163,215 - $268,995	1,500 Added 26.59%	7,141 $1.26 Million
Q1 2022 May 06, 2022	BUY	$119.61 - $157.85 $481,789 - $635,819	4,028 Added 249.72%	5,641 $813,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $229,965 - $307,857	1,613 New	1,613 $249,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

Stay updated on Aia Group LTD with notifications on news.